Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen acquired In-Process R&D (IPR&D) Written Off in Acquisitions (legacy) ($M) ($M)
Form 10-K Consolidated Statements of Cash Flows / Acquisitions Note (XBRL)
Latest, Q4 2022
0
Period ended Dec 31, 2022
Change on a year earlier
–
0 in Q4 2021
History
9 quarters
Since Q2 2020
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired In-Process R&D (IPR&D) Written Off in Acquisitions (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 0 | – | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 0 | -100.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2021 | Sep 30, 2021 | 0 | – | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,505 | – | Form 10-Q (filed 2022-08-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 0 | – | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 0 | – | Form 10-Q (filed 2021-08-04) ↗ |
Cite this data
StockData. (2026). Amgen Acquired In-Process R&D (IPR&D) Written Off in Acquisitions (legacy) ($M) ($M), quarterly Q2 2020–Q4 2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/rd_iprd_exp
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.